Clinical Trial Update: A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing Sacituzumab Govitecan plus Toripalimab versus Toripalimab plus Nab-Paclitaxel in PD-L1 positive advanced triple-negative breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Sacituzumab Govitecan (sacituzumab govitecan)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING